# Dose Response Study of VA106483 in Males With Nocturia and Benign Prostatic Hypertrophy (BPH)

> **NCT01330927** · PHASE1 · COMPLETED · sponsor: **Vantia Ltd** · enrollment: 30 (actual)

## Conditions studied

- Nocturia
- Benign Prostatic Hypertrophy (BPH)

## Interventions

- **DRUG:** VA106483

## Key facts

- **NCT ID:** NCT01330927
- **Lead sponsor:** Vantia Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03
- **Primary completion:** 2011-07
- **Final completion:** 2011-07
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2011-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01330927

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01330927, "Dose Response Study of VA106483 in Males With Nocturia and Benign Prostatic Hypertrophy (BPH)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01330927. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*